{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"179"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"201"}],"units":"Participants"}],"groups":[{"description":"Intravenous Pro-netupitant/Palonosetron (260 mg/0.25 mg) powder for solution for infusion (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle\n\nPro-netupitant/Palonosetron\n\nDexamethasone","id":"OG000","title":"Pro-netupitant/Palonosetron Plus Dexamethasone"},{"description":"Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle\n\nNetupitant/Palonosetron\n\nDexamethasone","id":"OG001","title":"Netupitant/Palonosetron Plus Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":">24-120 hours","title":"Percentage of Patients With no Significant Nausea (VAS <25 mm) During the Delayed Phase","type":"SECONDARY","unitOfMeasure":"Participants"}